Premium
β‐amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Author(s) -
Wiltfang Jens,
Esselmann Hermann,
Smirnov Alexander,
Bibl Mirko,
Cepek Lukas,
Steinacker Petra,
Mollenhauer Brit,
Buerger Katharina,
Hampel Harald,
Paul Sabine,
Neumann Manuela,
Maler Manuel,
Zerr Inga,
Kornhuber Johannes,
Kretzschmar Hans A.,
Poser Sigrid,
Otto Markus
Publication year - 2003
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.10661
Subject(s) - cerebrospinal fluid , pathology , alzheimer's disease , peptide , amyloid (mycology) , differential diagnosis , degenerative disease , medicine , disease , gel electrophoresis , biology , microbiology and biotechnology , biochemistry
Decreased levels of β‐amyloid peptide 1‐42 (Aβ1‐42) in cerebrospinal fluid (CSF) are a characteristic feature of Alzheimer's disease (AD) but recently were also observed in Creutzfeldt–Jakob disease (CJD). We analyzed the CSF of patients with CJD, and AD and nondemented controls using a quantitative urea‐based Aβ sodium dodecyl sulfate polyacrylamide gel electrophoresis immunoblot. Like in AD and nondemented controls, we found a highly conserved pattern of carboxyterminally truncated Aβ1‐37/38/39 in addition to Aβ1‐40/42 also in CJD patients. By the introduction of the ratio Aβ1‐39 to Aβ1‐42, CJD and AD can effectively be differentiated. We conclude that the immunoblot shows disease‐specific CSF Aβ peptide patterns in CJD and AD and suppose that measurement of the Aβ peptide pattern seems to be a promising diagnostic tool in the differential diagnosis of dementias. Ann Neurol 2003;54:263–267